ImmunoGen Gets $6.5M Milestone Fee

Ryan McBride3/3/09

ImmunoGen, a Waltham, MA-based developer of cancer treatments, says that it expects to collect a $6.5 million milestone from its partner, South San Francisco-based biotech giant Genentech, due to the start of dosing patients in a late-stage clinical trial for breast cancer drug T-DM1. The drug includes ImmunoGen’s cancer cell-killing agent linked to Genentech’s antibody trastuzumab, which targets the HER2 protein associated with metastatic breast cancer.